VINEETLAB logo

Vineet Laboratories Limited Stock Price

NSEI:VINEETLAB Community·₹382.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

VINEETLAB Share Price Performance

₹41.48
-9.12 (-18.02%)
₹41.48
-9.12 (-18.02%)
Price ₹41.48

VINEETLAB Community Narratives

There are no narratives available yet.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Fair value with mediocre balance sheet.

3 Risks
1 Reward

Vineet Laboratories Limited Key Details

₹584.5m

Revenue

₹571.0m

Cost of Revenue

₹13.4m

Gross Profit

₹180.4m

Other Expenses

-₹167.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-18.11
2.30%
-28.57%
300.8%
View Full Analysis

About VINEETLAB

Founded
2016
Employees
57
CEO
Gaddam Ramana
WebsiteView website
vineetlabs.co.in

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Recent VINEETLAB News & Updates

Recent updates

No updates